Company Analysis

Stoke Therapeutics, Inc. (STOK)

Nasdaq: STOK · Pharmaceutical Preparations · Bedford, MA · filing with the SEC since 2014
Grade6.3
◀ Past 5.4● Present 6.9▶ Future 6.6
1 est.

Who runs Stoke Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Kaye Edward M. Md
CEO. First filing Jun 2019, latest Aug 18, 2026, 16 filings in all.
Officers reporting now
8
of 15 people with a filing in the last fifteen months
Directors reporting now
7
21 people on the record since 2019
Officerssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Ticho BarryCHIEF MEDICAL OFFICERJun 2019Nov 4, 202628 · $1.9M
Allan JonathanGENERAL COUNSEL & CORP SECMar 2023Oct 2, 202622 · $1.3M
Kaye Edward M. MdCEOJun 2019Aug 18, 202614 · $1.4M
Mccauley ThomasChief Scientific OfficerJul 2026Jul 17, 2026none
Tzianabos ArthurInterim Executive ChairJun 2019Jun 5, 20261 · $200,000
Leggett ThomasChief Financial OfficerMay 2024Mar 19, 20265 · $100,000
Hoitt JasonChief Patient OfficerJun 2025Mar 19, 20265 · $100,000
Smith Ian FChief Executive OfficerSep 2023Feb 19, 2026none
Directorssales are open-market, Nov 4, 2025 to Nov 4, 2026
NameRoleFirst filingLatest filingSales, 12 months
Cumbo AlexanderdirectorSep 2026Sep 25, 2026none
Harrison Seth LoringdirectorJun 2019Jul 17, 2026none
Burstein JenniferdirectorJun 2019Jun 5, 2026none
Krainer Adrian R.directorJun 2019Jun 5, 20265 · $3.9M
Levin Arthur AdirectorJun 2019Jun 5, 20261 · $0.00
Smith JuliedirectorJun 2020Jun 5, 2026none
Kahn ClaredirectorApr 2026Apr 7, 2026none
Earlier names on the record16, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton STOK · research, not advice